What to Know About the Recent Eye Drop Recalls - The New York Times

Global Pharma recalled eye drops in February after they were tied to a drug-resistant bacteria strain that has since been linked to at least four deaths. Two other companies have also recalled eye drops.

Two brands of eye drops were pulled from shelves in January and February after they were linked to a drug-resistant bacteria strain that has been found to have caused at least four deaths and serious health issues in several others. Weeks later, two other types of eye drops were recalled because they posed a different kind of contamination risk. Dropper Container

What to Know About the Recent Eye Drop Recalls - The New York Times

This flurry of recalls may have you second-guessing your trusted source of dry-eye relief, but there are significant differences among the recalls and plenty of steps you can take to stay safe.

“I would encourage all people out there who take eye drops to continue using them, of course making sure that they’re not using any of these that are recalled,” said Dr. Christopher Starr, a clinical spokesman for the American Academy of Ophthalmology.

Here’s what to know about these recalls.

In January, the Centers for Disease Control and Prevention and the Food and Drug Administration warned people to stop using EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears after the eye drops were linked to a drug-resistant strain of the bacteria Pseudomonas aeruginosa. Infections from this bacteria strain have caused at least four people’s deaths, vision loss in 14 others and the surgical removal of four people’s eyeballs.

Global Pharma, which makes EzriCare and Delsam Pharma’s eye drops, recalled both products in February.

In March, a woman in Florida sued Global Pharma, claiming that an infection caused by the eye drops was so severe that doctors had to surgically remove one of her eyes.

The F.D.A. has also warned people to stop using an eye ointment manufactured by Global Pharma because of possible contamination.

The two other eye drop recalls were not linked to the bacteria outbreak.

On March 1, Apotex recalled prescription eye drops used to reduce eye pressure in people with glaucoma or ocular hypertension. The company recalled six lots of Brimonidine Tartrate Ophthalmic Solution 0.15 percent because at least four bottle caps developed cracks, which could affect the product’s sterility.

On March 3, Pharmedica recalled two lots of Purely Soothing 15 percent MSM Drops because they were not sterile. These drops are used to treat eye irritation and swelling.

The C.D.C. said that, as of May 15, the drug-resistant bacteria strain linked to the recalled EzriCare and Delsam eye drops had been found in 81 people in 18 states.

The best way to find out if you have eye drops that were included in the recall is to review the recall notice provided by each company. Each notice has details on which batch of each product was affected.

The notice for the EzriCare and Delsam eye drops is here, and the notice for the Global Pharma eye ointment is here. The Apotex Brimonidine Tartrate notice is here and the Pharmedica Purely Soothing notice is here.

People who have used these artificial tears and who have symptoms of an eye infection should see a doctor immediately, the C.D.C. said. The symptoms can include yellow, green or clear discharge from the eye, redness of the eye or eyelid, increased sensitivity to light and eye pain or discomfort.

Apotex said that people who received its recalled eye drops, which were distributed between April 5, 2022, and Feb. 22, should contact their health care provider and pharmacy. The company also provided a phone number and website for people to request a “recall/return packet.”

An Apotex vice president, Jordan Berman, said in an email that the company had seen only four bottles with cracked caps. He said that one of the bottles was from a customer or consumer complaint and the other three were found in retained samples — products that the F.D.A. requires a company to keep back in case issues like these arise.

“There have been no drug safety reports related to negative health outcomes due to this product,” Mr. Berman said.

Pharmedica said that, as of March 3, it had not received any reports of illness or other “adverse events” from the use of the eye drops. The company did not specify how many bottles were affected or how the bottles became not sterile.

Anyone who has issues with any of the recalled eye drops can file a report with the F.D.A. online, by mail or by fax.

Dr. Barbara Tylka, an optometrist at the Mayo Clinic in Rochester, Minn., said that, in general, eye drops are safe to use and that many people need them to treat conditions such as dryness or irritation. About 117 million Americans used eye drops and eyewash in 2020, according to Statista, a market research firm.

To use eye drops safely, Dr. Tylka said that people should use their own bottle and make sure it has not expired. People who have had eye drops prescribed to them for a procedure such as cataract surgery should stop using those products once the healing process is over, she said.

To safely apply eye drops, she said, people should use their nondominant hand to “gently tug on the lower eyelid, look up slightly,” and then, with the dominant hand, put “that little drop in that lower cul-de-sac in the eyelid area.”

Dr. Starr, an associate professor of ophthalmology at Weill Cornell Medicine, said that one thing some patients do wrong is press the bottle tip into the inner corner of the eye, which can contaminate the drops and scratch the surface of the eye. He said that when he accidentally hits his eyelid or eyelashes with the bottle tip, he considers the bottle contaminated and either resterilizes it or replaces it.

Dr. Starr and Dr. Tylka both emphasized that, while the recalls were worrying, eye drops are generally safe.

“I’ve continued to use eyedrops every day throughout this whole thing,” Dr. Starr said.

What to Know About the Recent Eye Drop Recalls - The New York Times

Hair Oil Bottle With Dropper Cap Amanda Holpuch is a general assignment reporter. More about Amanda Holpuch